Terminated PHASE4 INTERVENTIONAL 2-arm NCT00838682

Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers

Sponsor: Janssen Korea, Ltd., Korea

Interventions Rabeprazole omeprazole sodium IV

Updated 7 times since 2017 Last updated: Aug 31, 2010 Started: Apr 30, 2006 Primary completion: Jan 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated before the complete enrollment due to slow enrollment

Other terminated trials from Janssen Korea, Ltd., Korea

See all terminations from Janssen Korea, Ltd., Korea

Other Peptic Ulcer Hemorrhage trials with similar outcome

Browse all Peptic Ulcer Hemorrhage trials

Listed as NCT00838682, this PHASE4 trial focuses on Peptic Ulcer Hemorrhage and remains terminated or withdrawn. Sponsored by Janssen Korea, Ltd., Korea, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE4
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Korea, Ltd., Korea
The Catholic University of Korea

Data source: The Catholic University of Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bucheon-si, South Korea
• Uijeongbu-si, South Korea